SCHEMBL4773148

SCHEMBL4773148

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
PTPN1 P18031 1/20 0.49
NR1H4 Q96RI1 1/20 0.47
POLB P06746 2/20 0.46
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
GRM2 Q14416 1/20 0.44
AR P10275 2/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
PGR P06401 3/20 0.44
GAA P10253 1/20 0.43
KEAP1 Q14145 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775349 0.83 LMNA (0.41) ALDH1A1SMN1; SMN2LMNAPTPN1NR1H4
SCHEMBL4777413 0.83 KDM4E (0.52) ALDH1A1LMNAPOLBHPGDPGR
SCHEMBL4775267 0.83 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNANPC1HPGD
SCHEMBL4773540 0.82 GAA (0.43) ALDH1A1SMN1; SMN2LMNANR1H4POLB
SCHEMBL4771201 0.80 LMNA (0.50) ALDH1A1SMN1; SMN2LMNAPOLBMMP2
SCHEMBL4769790 0.80 KDM4E (0.44) ALDH1A1SMN1; SMN2LMNANR1H4POLB
SCHEMBL4772377 0.79 PNMT (0.47) ALDH1A1SMN1; SMN2LMNAPTPN1POLB
SCHEMBL4777553 0.79 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2LMNAPOLBGAA
SCHEMBL4777644 0.78 GAA (0.45) ALDH1A1SMN1; SMN2LMNAPTPN1NR1H4
SCHEMBL4772365 0.78 GAA (0.50) ALDH1A1SMN1; SMN2LMNANR1H4GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ALDH1A1 2159/4885SMN1; SMN2 1149/4885LMNA 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.